ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics listed on Aug 17, 2026. Q1 FY27 saw Total Income of ₹411.5 Cr and EBITDA of ₹103.7 Cr, transitioning from a loss in Q1 FY26 driven by higher test-kit consumption.
Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr and PAT of ₹52.74 Cr, a swing from prior-year losses. Growth was driven by Truenat test-kit volume and deferred Gulf export orders.
Molbio Diagnostics Ltd reported revenue from operations of ₹408.4 Cr (+309.6% YoY) and net profit of ₹52.7 Cr for Q1 FY27.
Molbio Diagnostics Limited scheduled a board meeting for September 5, 2026, to approve the unaudited standalone and consolidated financial results for the June 2026 quarter.
Molbio Diagnostics Limited has designated Mr. Darshan Raghunath Karekar as the company's Compliance Officer under the SEBI (Prohibition of Insider Trading) Regulations, 2015.